On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward defensive positions amid economic uncertainty.

Nearly 300 employees in Lawrenceville will lose their jobs as part of a pharmaceutical company's major cost-cutting measures, officials said.Bristol Myers Squibb will lay off at least 290 employees in ...

Bristol-Myers Squibb has become the latest drugmaker ... a decision to deny its rebate plan for big-selling blood thinner Eliquis (apixaban) under the 340B federal drug discount programme ...

Bristol-Myers Squibb Co. (BMY) traces its corporate beginnings back to 1887. Today, the company is a leader in developing innovative drugs like Eliquis for stroke prevention and Opdivo for cancer ...

Bristol-Myers Squibb Company discovers ... The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) has been assigned a consensus rating of “Hold” from the nineteen brokerages that are covering the company, Marketbeat.com reports. Two research ...

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition. Karuna’s crown jewel, an ...